Reply to "Subcutaneous terbutaline as an alternative to aerosolized albuterol".
Document Type
Response or Comment
Publication Date
7-2020
Identifier
DOI: 10.1016/j.jaip.2020.04.016; PMCID: PMC7174169
Abstract
Comment on
- COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic. Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N, Hsieh EWY, Rider N, Dutmer CM, Vander Leek TK, Kim H, Chan ES, Mack D, Ellis AK, Lang D, Lieberman J, Fleischer D, Golden DBK, Wallace D, Portnoy J, Mosnaim G, Greenhawt M.J Allergy Clin Immunol Pract. 2020 May;8(5):1477-1488.e5. doi: 10.1016/j.jaip.2020.03.012. Epub 2020 Mar 26.PMID: 32224232 Free PMC article. Review.
- Subcutaneous terbutaline as an alternative to aerosolized albuterol. Strauss RA.J Allergy Clin Immunol Pract. 2020 Jul-Aug;8(7):2450. doi: 10.1016/j.jaip.2020.04.015. Epub 2020 Apr 20.PMID: 32336646 Free PMC article. No abstract available.
Journal Title
J Allergy Clin Immunol Pract
Volume
8
Issue
7
First Page
2450
Last Page
2452
MeSH Keywords
Albuterol; COVID-19; Humans; Hypersensitivity; Pandemics; SARS-CoV-2; Terbutaline
Keywords
Albuterol; COVID-19; Humans; Hypersensitivity; Pandemics; SARS-CoV-2; Terbutaline
Recommended Citation
Shaker MS, Oppenheimer J, Grayson M, et al. Reply to "Subcutaneous terbutaline as an alternative to aerosolized albuterol". J Allergy Clin Immunol Pract. 2020;8(7):2450-2452. doi:10.1016/j.jaip.2020.04.016
COinS
Comments
Grant support